A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Roswell Park Cancer Institute
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Pfizer
NRG Oncology
Sun Yat-sen University